© 2026 Sinochem Nanjing Corporation,
All Right Reserved
folks have always needed better ways to fight off infections. Cephalosporins took off thanks to Italian scientist Giuseppe Brotzu in the 1940s. After he spotted a mold in Sardinia dealing out antibacterial action, research teams started digging into the structure. That mold opened the door to cephalosporin C. Jumping forward, chemists realized building on the 7-aminocephalosporanic acid nucleus meant tweaking the core for stronger, broader drugs. For 7-Amino-3-Vinylcephalosporanic Acid (7-AVCA), that vinyl group at position 3 gave researchers a tool to make newer, more adaptable cephalosporins. These advances straight-up changed the way hospitals and clinics handle resistant bacteria.
Modern cephalosporin production starts with 7-AVCA as a backbone. Anyone working in antibiotics knows this compound as the gateway to whole classes of next-gen cephalosporins. It rolls out of factories typically as a crystalline solid, often off-white or yellowish, depending on purity and process quirks. Labs use it not for direct medical purposes, but as the raw chemical for further synthesis. The moment a new cephalosporin enters the market, odds are high its story started with this very compound.
Anybody who's handled 7-AVCA in a lab sees right away it's not your everyday chemical. It melts between about 220–240°C, usually decomposing before reaching boiling point, a behavior expected from many beta-lactam compounds. Water solubility ranges from moderate to low, though organic solvents like dimethylformamide open up its handling options. With a molecular weight circling 316–320 g/mol, it stands sturdy enough for manipulation under standard lab equipment. The defining character comes from its beta-lactam ring, the vinyl at the 3-position, and amino at the 7-position—each crucial for how it reacts downstream in pharmaceutical chemistry.
Suppliers stick clear, standard labels on each container, showing product code, net quantity, chemical name, and batch numbers needed for traceability in pharmaceutical production. Storage instructions matter, since cephalosporin derivatives can degrade if exposed to moisture and light. Labels often warn against inhalation and unnecessary skin contact. Certificates of analysis matter as much as any shipment, showing spectroscopic data, purity—almost always above 98 percent—and confirmation there’s no beta-lactamase contamination. Anybody putting this material into reactors wants to see tech sheets laying out melting point, solubility, and HPLC purity before even opening the lid.
Chemical production usually starts from cephalosporin C or its derivatives, cleaving side chains enzymatically or chemically. Then comes vinylation at position 3, often by the action of vinyl esters under controlled pressure and temperature. Many methods use palladium catalysis, giving cleaner conversion. Adjusting pH, temperature, and solvent keeps yield and purity up. Some routes go the biotechnological way, engineering bug strains to pump out precursors and refining them through standard purification columns. Anyone doing scale-up knows time, solvent recycling, and the cost of palladium all show up on the balance sheet.
For the medicinal chemist, the best thing about 7-AVCA lies in that reactive amino group at position 7 and the vinyl at position 3. Both open the door for all sorts of custom tailoring. The 7-amino side chain gets swapped out with new acyl groups, creating familiar antibiotics like ceftazidime or cefixime. The 3-vinyl group, through ozonolysis or hydrogenation, turns into all sorts of functionalities, tweaking spectrum or pharmacokinetics. Working with this scaffold demands clean, moisture-free conditions, and any side reactions or leftover palladium must get chased out with meticulous purification. Contaminants have no place in APIs bound for clinical trials.
Walking through any chemical supplier’s catalog, 7-AVCA might show up under a few different names. The full IUPAC name confuses most non-chemists: (6R,7R)-7-Amino-3-vinyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, for starters. Many factories just call it ceph-3-vinyl-7-ACA, especially on lab orders. No matter what, the structure stays the same, but knowing the synonyms helps avoid costly ordering mistakes. Safety data sheets all refer back to its core identity, which streamlines regulatory workflows in global pharmaceutical trade.
Anybody handling 7-AVCA in a production setting keeps respirators, gloves, and face shields close. The powdery solid, like most beta-lactams, carries a risk of allergic sensitization in workers—and cross-contamination can wreak havoc on sterile plant runs. Regular air sampling and wipe-down of surfaces make up the daily grind in API manufacturing. Waste solvents containing cephalosporanic acids never go down the standard drain, heading off to chemical treatment or incineration per government rules. Proper storage means cool, dry rooms with access control so unauthorized personnel stay clear. Training for accidental spill response stays on repeat in GMP environments, since once a powder cloud gets loose, containment becomes tricky.
Folks in the pharmaceutical industry favor 7-AVCA as the starting point, not the destination. It’s the launchpad for dozens of injectable, oral, and topical antibiotics. Paint a broad stroke across hospitals worldwide and you’ll see cephalosporins treating everything from strep throat to bone infections caused by resistant bugs. Medicinal chemists depend on this scaffold not just for old-generation cephalosporins, but also for discovering new candidates in the arms race against superbugs. Scientists in veterinary medicine also grab up this compound when formulating drugs for livestock, where bacterial infections can devastate whole flocks or herds.
Having access to pure 7-AVCA allows research teams to crank out new side chains fast, testing them against panels of increasingly nasty bacteria. Most research groups keep a stash on hand, since each year brings new resistance profiles that send teams back to the drawing board. Ongoing programs focus on boosting oral bioavailability, cutting dosing frequency, or extending spectra into multi-drug resistant Gram-negatives. Partnering chemical innovation with rapid microbial screening lets companies stay ahead of regulatory and market needs. The timeline from bench to bedside shrinks when chemists can trust the consistency and activity of their starting 7-AVCA.
Working with beta-lactam structures always means watching for allergic reactions in both animal tests and manufacturing staff. Studies on 7-AVCA’s acute toxicity find side effects line up with broader cephalosporin risks—rashes, anaphylaxis, and, at high doses, kidney impacts. Most reported occupational health incidents trace back to dust exposure or poor ventilation controls. Ongoing toxicity screens in animal models help set safe exposure limits in both research and industrial settings. In my own time supervising small-scale synthesis, I’ve seen monthly health checkups save staff from long-term sensitivity by tracking early signs. Companies invest in continuous education, since new synthesis routes can switch up risk levels on short notice.
As world health agencies warn about the rise of hard-to-treat infections, the need for flexible, reliable antibiotic building blocks like 7-AVCA rises. Scientific interest pushes toward custom-tuning cephalosporins for everything from tailored infection management to new forms that dodge resistance mechanisms. Breakdown of complex bacterial defenses sometimes means sending this chemical nucleus through cycles of modification and bioassay, grinding toward better pills, powders, and injectables. Smart factories test automation and green solvents to cut costs and environmental burden, keeping one eye on regulatory changes. Next-generation drugs built off 7-AVCA will help set the tone for fighting resistant bugs in hospitals and on farms alike, shaping how populations weather the coming decades of microbial challenges.
Just saying the name, 7-amino-3-vinylcephalosporanic acid, makes it sound like something only folks in white coats ever talk about. In reality, this compound sits at the core of antibiotic medicine building and has impacted more lives than most people realize. My background working with pharmaceutical projects at the university gave me some direct exposure to these raw materials. I remember standing in the lab holding a small sample, thinking—this is the backbone for a set of drugs a lot of people rely on.
Modern treatments for tough infections grew out of breakthroughs in the field of cephalosporins, and that's where this compound plays its major part. Chemists see it as a framework—a skeleton they can build on. Pharmaceutical companies add different side chains to this molecule, searching for new drugs with unique strengths against bacteria that keep learning to outsmart existing treatments. The World Health Organization has flagged antibiotic resistance as one of the biggest ongoing threats to our health. For every new version bacteria outmaneuver, scientists need a new plan.
From what I’ve seen, the search isn’t about immediately inventing brand new antibiotics each time resistance turns up. Researchers tweak pieces, like with 7-amino-3-vinylcephalosporanic acid. They use this core to create fresh weapons, like ceftazidime, which first appeared in the 1980s. Over decades, cephalosporins have treated everything from pneumonia to wound infections. According to recent data from the Centers for Disease Control and Prevention, over 2.8 million antibiotic-resistant infections occur every year in the U.S. The need for reliable antibiotic starting materials hits closer to home every year.
One challenge I heard commonly discussed is the complex process of making these starting molecules. Growing up in a community with a local API manufacturing unit, I saw how environmental concerns tied directly to pharmaceutical factories. Waste management comes up often, especially with complex cephalosporin production. We need cleaner, more sustainable chemical processes. Some newer manufacturing techniques use enzymes to help form the desired molecules, cutting down on harsh chemicals and waste. These bio-based routes could help reduce the environmental footprint. Universities with a focus on green chemistry, like Yale, actually publish protocols that smaller manufacturers can follow to improve their practices. Seeing this information driven by real-world need rather than just market trends gives me hope.
Another major concern centers around supply chain vulnerability. Many ingredients for critical drugs, including cephalosporin precursors, travel through multiple countries before reaching medicine cabinets. Any hiccup—political squabble, natural disaster, unexpected demand spike—can set off drug shortages. I spoke once with a small hospital pharmacist who described the scramble to find substitutions during a shortage of a common antibiotic. Investing in more decentralized manufacturing and keeping robust stocks could cushion the blow. Agencies like the FDA have started tracking and publishing data on which compounds are most at risk, nudging companies to plan smarter.
It’s all too easy for stories like this to feel distant—just chemical puzzles or manufacturing problems. From my perspective, 7-amino-3-vinylcephalosporanic acid turns into medicines you or people you care about may already depend on. Its future depends on building both smarter science and stronger systems for turning ideas into reliable care. Respecting the work done at each stage—from laboratory bench to pharmacy shelf—keeps me optimistic that real solutions will follow.
Focusing on the chemistry behind antibiotics, 7-Amino-3-Vinylcephalosporanic Acid stands out. Scientists know it by the shorthand “7-AVCA.” The core structure hangs onto a bicyclic system called the β-lactam ring, which couples with a dihydrothiazine ring. These rings form the heart of all cephalosporins. Picture a four-membered β-lactam ring fused to a six-membered thiazine ring, creating a rigid, almost stubborn backbone. Off one position—the third carbon—swings a vinyl group, basically a small hydrocarbon tail with a double bond. On the seventh carbon sits the amino group, a common entry point for chemical tinkering in drug development.
Traditional antibiotics like penicillin also use the β-lactam ring, but cephalosporins wear an extra ring for better resilience. Hospitals constantly fight bacteria that shrug off old antibiotics. The double-ring system in molecules like 7-AVCA increases resistance to certain bacterial enzymes. That extra layer saves lives every day in clinics where infections quickly spin out of control.
Walking through a hospital ward packed with infection cases, it’s hard to overstate the public health value in this basic chemical framework. Hospitals lean on cephalosporins as bacteria keep evolving. Without the stability that comes from this sturdy structure, many modern therapies would stumble. For every patient spared a drug-resistant infection, the chemical structure of 7-AVCA has played a supporting role, even if its name never comes up during treatment rounds.
Medicinal chemists rely on the 7-AVCA core to build new antibiotics with improved characteristics. The amino group at the seventh position opens avenues for attaching all sorts of molecular side chains. These changes can make compounds more active against stubborn germs or less prone to breakdown in the body. The vinyl group at the third carbon acts as a platform for creating analogues that fine-tune drug properties. The chemical structure, plain on paper, becomes a playground for innovation in real labs.
Take the fight against Escherichia coli and Staphylococcus aureus, frequent troublemakers in clinical settings. Tweaking side chains attached to the 7-AVCA scaffold delivers cephalosporins that keep working even as those bacteria plot new ways around older drugs. This strategy has carried through several generations of antibiotics, each step building off this simple core.
Scientists have hit barriers, too. Bacteria eventually roll out enzymes that chew up even the best-designed drugs. Researchers have started pairing cephalosporin-derived molecules with enzyme blockers, using the strengths of the 7-AVCA core as a foundation. This approach has kept more people out of the intensive care unit.
On a larger scale, keeping the pipeline of new antibiotics flowing requires ongoing investment in chemistry education and lab resources. Training scientists to recognize the value in apparently simple changes—like swapping out a side chain or adding a blocker—keeps cephalosporins like those based on 7-AVCA relevant. The entire ecosystem, from grad students to pharmaceutical companies, benefits when society understands that the chemical blueprint of these antibiotics holds the key to future cures.
7-Amino-3-Vinylcephalosporanic Acid represents more than a tongue-twister for chemists. As a key intermediate for important antibiotics, any mishap affects research, manufacturing, and ultimately the supply of life-saving medicines. Nobody in the laboratory wants to see wasted batches, spiking costs, or contaminated product.
Over ten years around chemical storerooms, I’ve watched longer ingredient lists, tighter quality controls, and more eyes on every flask. Problems often sneak in through storage. A slight lapse in temperature control or careless humidity exposure leads to breakdowns. Staff end up tossing months of effort and money after reacting to one compromised barrel.
7-Amino-3-Vinylcephalosporanic Acid happens to be prone to decomposition. Treating every kilo as a high-value item never hurts. The compound breaks down much faster if exposed to direct sunlight, even through lab windows. It doesn’t survive for long in warm or humid corners either. My own early mistake once led to a sticky mess clinging inside a plastic bottle that refused to wash out. Throwing away good chemistry feels worse after catching a faint whiff of old, off-balance cephalosporin.
The right commercial practice means keeping storage temperatures on the cool side, usually under 8°C (that’s fridge cold, not room temperature). Laboratories with regular power cuts or weak refrigeration see higher failure rates. Reuters and the FDA both reported very public recalls after improper storage at the wholesaler’s warehouse sent active contents tumbling. Integrity and public trust both suffer fast when users ignore standard operating procedures.
Old school glass containers sealed with rubber stoppers once dominated. Switches to high-grade plastics or foil-lined bags stop moisture leaks much more effectively. A double-layer approach gets used for larger shipments, and nobody wants to save a few pennies just to risk their batch. Folding a new label over every restock cuts confusion: date of receipt, opened date, and expiration in big, clear print. Missing any one of these steps means tracking down bad batches later, sometimes weeks after the mistake.
Even with good containers, reckless handling spreads micro-cracks and weakens shelf life. Splitting shipments or moving part-used bags between departments opens doors for accidental contamination. I’ve watched more than one box slide off a dolly in a freezer with ten other busy lab coats nearby—the compound absorbs water from the air quickly, even at low temperatures, so broken seals ruin product before workers notice.
I’ve learned the hard way that every link in the chain matters. The solution isn’t just slapping on a “store in cool, dry place” sticker. Staff training, regular inspections, strict logs for each lot, and clear lines of accountability close the gap. Backup refrigeration and quick-response quarantine bins limit damage when things slip. Even automated trackers, using barcodes or digital thermometers, make it easier to spot a problem early.
Quality assurance requires real vigilance each step of the journey. The risk of spoiled product, lost investment, or safety concerns always outweighs any shortcut. Each shipment of 7-Amino-3-Vinylcephalosporanic Acid needs a careful hand and sharp attention—lives and health down the road often depend on getting storage right.
Any person who has worked in pharma R&D knows purity isn’t just a technical term tossed around in meetings. Companies rely on 7-Amino-3-Vinylcephalosporanic Acid, or 7-AVCA, for making cephalosporin antibiotics that end up in hospitals and clinics. Purity of raw materials becomes personal when you realize what’s at stake—one batch off-spec, and patient treatments derail, regulatory filings go back to the drawing board, and trust evaporates. Having seen audit teams pore over chromatograms and test results for hours, it’s obvious the source and grade of 7-AVCA matter deeply.
7-AVCA doesn’t come in a one-size-fits-all form. Not every supplier treats purity the same way, and for buyers, that opens a whole can of worms. Research labs grab small lots for exploratory work, so a less-refined sample might do the trick. Industrial plants running full-scale blending or synthesis need robust, highly pure material—no argument. Purity grades often get split along these lines, such as “research grade,” “technical grade,” and “pharmaceutical grade,” though the actual labels may change depending on the supplier.
Hazards pile up when distinctions blur. Lower grades might carry trace residual solvents, water, or even unreacted intermediates. Anyone who’s spent hours on method validation in a GMP lab knows these details translate to major headaches if missed. FDA warning letters often mention “failure to adequately characterize raw materials”—this isn’t nitpicking: contaminants in 7-AVCA could impact stability, shelf life, or even trigger rare adverse immune responses in end products.
I hear from peers that some teams assume an “average” purity threshold will cover everything. Real-world clinical manufacturing shreds that notion. Documented failures, from inconsistent lot-to-lot quality to undissolved particles during formulation, all point back to poor control at the start. One company in the news last year traced an entire recall to a less rigorous grade of an antibiotic intermediate. Chain reactions get set off downstream.
Tough discussions pop up during tech transfer or scale-up: someone asks “Can we save money by lowering the starting grade?” Any experienced process chemist knows this shortcut ends up costing more. GMP guidance from both the FDA and EMA requires clear traceability and justification for each input, especially with beta-lactam antibiotics. Not every supplier will certify trace impurities—some point to legacy specifications never updated since the 90s. Instinct says always get a certificate of analysis and, if possible, visit the factory at least once. I've seen unexpected contamination from re-used glassware or shared equipment lines in smaller outfits.
More collaboration stands out as the most immediate fix. Manufacturers and suppliers should run joint reviews of analysis reports, not just swap purchase orders by email. Involving independent labs for batch-by-batch validation adds a cushion of trust, especially if development timelines are tight. Industry groups could push for more harmonized standards for 7-AVCA, shifting away from proprietary “house standards” toward transparent regional minimums. That would spare smaller players the whiplash of figuring out if a given grade is truly fit for its intended purpose.
Every discussion on this topic circles back to patient health. Cutting corners on grade or purity never stays hidden for long. When antibiotic resistance and drug recalls threaten real-world care, making sure 7-AVCA meets specs feels less like paperwork and more like proper stewardship in a high-stakes industry.
7-Amino-3-vinylcephalosporanic acid, often found in the world of antibiotic development, carries the CAS number 61270-58-6. This identifier traces directly to a compound that has shaped the field of cephalosporin antibiotics for decades. Understanding the relevance of this number can save headaches for scientists, lab techs, and regulatory teams working in the pharmaceutical pipeline. Trying to track down reliable chemical information online without a CAS number leads to wasted time and uncertainty, especially when chemical synonyms and international trade names muddy the search results. The system isn’t perfect, but the CAS registry number offers a direct route for clarity in a confusing landscape.
Chemistry runs on precision. For someone handling substances with slight differences that pack huge consequences — for a recent graduate or even a company vet — typing a structure or relying on a common name often leads to mistakes. CAS numbers, like 61270-58-6 for 7-amino-3-vinylcephalosporanic acid, offer a universal language that everyone from Beijing to Boston can rely upon for ordering, documentation, and safety records. I’ve seen teams waste hours sorting out orders because a supplier used a brand name and another used an obsolete synonym. Confusion slows research, burns through budgets, and sometimes results in the wrong chemical being shipped halfway around the globe.
This compound is not just another lab reagent sitting on a shelf. It stands as a key starting material for a wide class of cephalosporin antibiotics. These lifesaving drugs step in where penicillins fall short, especially against resistant bacteria. Chemists count on 7-amino-3-vinylcephalosporanic acid as a backbone for modifying side chains and creating new derivatives that target tough infections. The benefits ripple out from the chemist’s bench to the hospital ward, extending the life and reach of antibiotics we rely on when infection won’t let up.
In practice, I’ve felt the relief that comes from finding a precise CAS number in a sea of confusing data sheets. Laboratories can order the right intermediate, regulators have a clear identifier that links to safety profiles and clinical data, and pharma companies meet compliance with health agencies in different countries. Mixing up even a single digit or ignoring the CAS number leads to delays, regulatory headaches, or worse — wasted batches and clinical trial holdups. In antibiotic production, time really does matter. Delays or mix-ups can halt an entire development project, ripple through research teams, and deprive clinicians of powerful tools against infection.
Simple steps make a difference. Embedding CAS numbers from day one in procurement, inventory management, and regulatory submissions streamlines everything. Open databases combining CAS, chemical names, and images allow quick double-checks. Training staff — especially new hires — to default to using CAS numbers prevents cascading errors. For students, highlighting the importance of identifiers in coursework anchors attention on the real-life risks of chemical mislabeling long before they enter the workforce.
Every small accuracy on the front end speeds up research, reduces production mistakes, and helps push life-saving antibiotics out the door faster. The CAS number for 7-amino-3-vinylcephalosporanic acid might look like just another catalog entry, but it marks a path through the maze of modern drug development toward a working medicine shelf.
| Names | |
| Preferred IUPAC name | (6R,7R)-7-amino-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Other names |
7-AVCA 7-Amino-3-vinyl-3-cephem-4-carboxylic acid |
| Pronunciation | /ˈsɛv.ən əˈmiː.nəʊ θri vaɪˈnɪl sɛfəˌloʊspəˈrænɪk ˈæsɪd/ |
| Identifiers | |
| CAS Number | 52824-03-6 |
| Beilstein Reference | 1707551 |
| ChEBI | CHEBI:47786 |
| ChEMBL | CHEMBL2105923 |
| ChemSpider | 26788 |
| DrugBank | DB04147 |
| ECHA InfoCard | ECHA InfoCard: 100.041.649 |
| EC Number | 258-993-2 |
| Gmelin Reference | 387639 |
| KEGG | C06238 |
| MeSH | D023217 |
| PubChem CID | 468756 |
| RTECS number | XI2100000 |
| UNII | CW2SO03KEF |
| UN number | 2811 |
| Properties | |
| Chemical formula | C10H11N3O4S |
| Molar mass | 327.362 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.75 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | -1.4 |
| Vapor pressure | 0.0 mmHg (25°C) |
| Acidity (pKa) | 2.7 |
| Basicity (pKb) | 3.02 |
| Magnetic susceptibility (χ) | -94.2e-6 cm³/mol |
| Refractive index (nD) | 1.68 |
| Dipole moment | 5.25 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 293.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -148.6 kJ/mol |
| Pharmacology | |
| ATC code | J01DD62 |
| Hazards | |
| Main hazards | May cause respiratory irritation. May cause allergic skin reaction. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Danger |
| Hazard statements | H315, H319, H334 |
| Precautionary statements | P264, P280, P302+P352, P305+P351+P338, P332+P313, P362+P364 |
| NFPA 704 (fire diamond) | 2-1-1-W |
| Lethal dose or concentration | LD50 oral rat > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): >5 gm/kg (oral, mouse) |
| NIOSH | NA7649000 |
| REL (Recommended) | 50 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Cephalosporin C Cephalexin Cephalosporanic acid 7-Aminocephalosporanic acid |
